Clinical trial NCT02245477: Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction
Official title: Evaluation of Maternal Serum VEGF in Pregnant Women With Foetal Growth Restriction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Foetal Growth Restriction
Keywords: Serum VEGF, FGR
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2014-09-19
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with gestational age 28-36 weeks were included in our study. Patients with SGA were defined by obstetric ultrasound as estimated fetal weight was below the10thcentile.Twice weekly CTGs and Umbilical artery (UA) Doppler were done. Women with abnormal CTGs or UA Doppler were excluded from the study. A follow up scan was done 2 weeks later and FGR will be diagnosed if fetal weight had faltered.

Brief summary: In this study we explore To explore the role of maternal serum vascular endothelial growth factor (VEGF) in pregnancies complicated by foetal growth restriction.

Detailed description: Small-for-gestational age (SGA) is defined as an estimated foetal weight (EFW) or abdominal circumference (AC) less than the 10th centileand severe SGA as an EFW or AC less than the 3rd centile. Foetal Growth Restriction refers to failure of the foetus to achieve its predetermined growth potential for various reasons.Foetus with foetal growth restriction (FGR) greatly contributes to perinatal mortality and short- and long-term morbidity. There is a 3-10 fold increase in perinatal mortality in pregnancies complicated by this FGR .The incidence of FGR in newborns ranges between 3 and 7% of the total population .FGR is thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels, leading to placental hypoperfusion and thus fetal undernutrition. However, the effects of hypoxia on the fetoplacental vessels have been surprisingly little studied.Vascular endothelial growth factor (VEGF) is one of the factors that take part in placental angiogenesis. It is highly expressed during embryonic and foetal development..Angiogenesis involves the branching of new microvessles from pre-existing larger blood vessels.Angiogenesis plays a role in the development of the villous vasculature and the formation of terminal villi in human placenta. IUGR occurs as a result of the failure of elongation, branching and dilatation of the capillary loops and of terminal villous formation.

Eligibility criteria: Inclusion Criteria:

* Age 20-40 years
* Gestational age 28-36 weeks
* Fetal growth restriction
* Patient consents to the procedure.
* BMI 20-30

Exclusion Criteria:

* Preeclampsia
* Diabetes Mellitus
* Fetal congenital anomalies

Primary outcomes:
measure: Obstetric ultrasound
timeFrame: from 28 weeks gestation to 36 weeks gestation
Secondary outcomes:
measure: Serum Vascular Endothelial growth factor
timeFrame: 3 months until delivery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Nesreen Abdel Fattah Abdullah Shehata
Study officials:
References: